tradingkey.logo
tradingkey.logo

Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition Of Preclinical Assets From Kezar Life Sciences

ReutersMar 12, 2026 1:23 PM

- Enodia Therapeutics:

  • ENODIA THERAPEUTICS STRENGTHENS SEC61 PORTFOLIO THROUGH ACQUISITION OF PRECLINICAL ASSETS FROM KEZAR LIFE SCIENCES

  • ENODIA THERAPEUTICS - KEZAR TO RECEIVE $1 MILLION UPFRONT AND UP TO $127 MILLION IN MILESTONE PAYMENTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

KeyAI